A site for medical students - Practical,Theory,Osce Notes


Medullary Carcinoma of the Thyroid: A Comprehensive Overview

Medullary thyroid carcinoma (MTC) is a rare but distinctive type of thyroid cancer that originates from parafollicular C cells, which produce the hormone calcitonin. Although it only accounts for about 1-2% of all thyroid cancers, MTC is often aggressive and can pose significant treatment challenges. This article explores the key aspects of MTC, from its pathogenesis to diagnosis and treatment options.

Understanding Medullary Thyroid Carcinoma

MTC is unique among thyroid cancers due to its origin from parafollicular C cells rather than follicular cells, which are the source of the more common papillary and follicular thyroid cancers. Elevated levels of calcitonin, a hormone produced by C cells, serve as a key indicator of MTC.

MTC can occur in two forms: sporadic (non-hereditary) or hereditary. About 75-80% of all MTC cases are sporadic, appearing randomly with no family history. The remaining 20-25% of MTC cases are hereditary and are associated with a genetic syndrome known as Multiple Endocrine Neoplasia type 2 (MEN2).

Signs and Symptoms

The clinical manifestations of MTC can vary. Some patients may notice a lump in their neck, while others may experience symptoms like hoarseness, difficulty swallowing, or a change in voice. Some people with hereditary MTC may not have any symptoms and the disease may be detected through genetic screening.

High levels of calcitonin may lead to symptoms such as diarrhea or flushing. In more advanced cases where the cancer has spread to other parts of the body, symptoms may include bone pain or shortness of breath.


MTC diagnosis involves a combination of physical examination, imaging studies, laboratory tests, and biopsy.

Elevated calcitonin levels can provide a key indication of MTC. However, a definitive diagnosis requires a biopsy, typically a fine-needle aspiration (FNA), where cells from the thyroid nodule are collected and examined under a microscope.

Imaging tests, such as ultrasound of the neck, computed tomography (CT), or magnetic resonance imaging (MRI), can help define the extent of the disease. For hereditary MTC, genetic testing is done to identify mutations in the RET (rearranged during transfection) proto-oncogene.


Surgery is the mainstay of treatment for MTC and often involves a total thyroidectomy, where the entire thyroid gland is removed. In cases where the cancer has spread to nearby lymph nodes, a lymph node dissection may also be performed.

Radioactive iodine, commonly used in other types of thyroid cancer, is generally ineffective in MTC as the C cells do not absorb iodine. Hence, external beam radiation therapy may be considered for certain patients, especially when there is extensive local disease or in cases of recurrence.

For advanced or metastatic disease, systemic therapies may be required. These include chemotherapy, targeted therapies, and immunotherapy. Targeted therapies such as tyrosine kinase inhibitors (like vandetanib and cabozantinib) have shown promise in treating advanced MTC.

Patients with hereditary MTC linked to MEN2 syndrome often undergo prophylactic thyroidectomy, removing the thyroid gland before cancer develops.


The prognosis for MTC varies widely and depends on several factors, including the stage of the disease, the patient's age, and whether the cancer is sporadic or hereditary. Early-stage MTC has a generally good prognosis, with a 10-year survival rate of about 95%. However, for individuals with advanced disease, the prognosis is more guarded, with 10-year survival rates dropping significantly.

Patients with hereditary MTC, especially those diagnosed through genetic screening before the onset of symptoms, often have a better prognosis than those with sporadic MTC. This is largely due to earlier detection and intervention in these cases.

The key to improving prognosis lies in early detection and prompt, appropriate treatment. Therefore, in patients with a known genetic predisposition, regular screening and preventative surgery are important measures.

Medullary thyroid carcinoma, while a small proportion of thyroid cancers, presents unique challenges in diagnosis and treatment due to its origin from parafollicular C cells and its potential to be a hereditary condition.

In the case of hereditary MTC, genetic counseling and testing are paramount in the management of the condition. For both sporadic and hereditary MTC, surgery is the mainstay of treatment, with systemic therapies playing a role in more advanced disease states. While promising strides have been made in understanding and managing MTC, ongoing research is crucial to continue improving outcomes for patients with this unique form of thyroid cancer.